Prednisone and losartan
Pro Research Analysisby 
Searched over 200M research papers
Prednisone and Losartan: Therapeutic Synergies and Applications
Introduction to Prednisone and Losartan
Prednisone, a corticosteroid, and losartan, an angiotensin II receptor blocker (ARB), are medications commonly used to treat a variety of conditions, including inflammatory diseases, hypertension, and certain kidney disorders. This article explores the combined effects and therapeutic applications of these drugs based on recent research findings.
Inhibition of Glomerular Mesangial Cell Proliferation
Keywords: Glomerular Mesangial Cells, Angiotensin II, TRPC6, Intracellular Calcium
Research has shown that angiotensin II (AngII) can induce the proliferation of glomerular mesangial cells (GMCs) by increasing intracellular calcium ion concentration ([Ca2+]i) and TRPC6 expression. Losartan effectively inhibits this proliferation by reducing TRPC6 levels and [Ca2+]i, thereby reversing the effects of AngII. Prednisone also inhibits GMC proliferation but does not affect TRPC6 expression or [Ca2+]i levels .
Corneal Scarring and Fibrosis Reduction
Keywords: Corneal Scarring, Myofibroblasts, Alkali Burn Injury
In a study on corneal alkali burn injuries in rabbits, the combination of topical losartan and prednisolone acetate significantly reduced corneal scarring and fibrosis. This combination therapy decreased the area and intensity of stromal myofibroblast staining and confined myofibroblasts to the posterior stroma, promoting the repopulation of keratocytes in the anterior and mid-stroma .
Renoprotection in IgA Nephropathy
Keywords: IgA Nephropathy, Proteinuria, Renal Function
A randomized controlled trial demonstrated that the combination of prednisolone and losartan is more effective than prednisolone alone in reducing proteinuria and protecting renal function in patients with IgA nephropathy. Over two years, patients receiving both medications showed a significant decrease in proteinuria and better preservation of creatinine clearance compared to those receiving only prednisolone .
Pulmonary Fibrosis Attenuation
Keywords: Pulmonary Fibrosis, Bleomycin, TGF-β1
Losartan has been found to attenuate bleomycin-induced pulmonary fibrosis in rats. The drug reduces the levels of hydroxyproline and malondialdehyde (MDA) in lung tissues while increasing superoxide dismutase (SOD) levels. Additionally, losartan decreases serum TGF-β1 levels, suggesting its potential in mitigating lung fibrogenesis through anti-free radical mechanisms and TGF-β1 reduction .
Renal Function Protection in Nephrotic Syndrome
Keywords: Nephrotic Syndrome, Proteinuria, Renal Tubular Protection
In patients with nephrotic syndrome, the combination of prednisone and losartan has shown protective effects on renal function. This combination therapy significantly reduced 24-hour urinary protein, urinary N-acetyl-β-D-glucosaminidase (uNAG), and urinary retinol-binding protein (uRBP) levels more effectively than prednisone alone, indicating enhanced renal protection .
Podocyte Molecule Stabilization in Nephrotic Rats
Keywords: Podocyte Molecules, Nephrin, CD2AP
Studies on adriamycin-induced nephrotic rats revealed that prednisone, enalapril, and losartan stabilize the expression and distribution of critical podocyte molecules, nephrin, and CD2-associated protein (CD2AP). This stabilization is associated with a significant reduction in proteinuria, suggesting that these drugs may help maintain podocyte integrity and function .
Anti-Arthritic and Anti-Inflammatory Effects
Keywords: Rheumatoid Arthritis, Inflammation, Oxidative Stress
Losartan has demonstrated beneficial effects in adjuvant-induced arthritis (AIA) in rats. It significantly reduced serum levels of inflammatory markers such as TNF-α and IL-6, as well as oxidative stress markers. Additionally, losartan improved lipid profiles and hematological parameters, indicating its potential as an anti-arthritic and anti-inflammatory agent .
Treatment of ANCA-Related Glomerulonephritis
Keywords: ANCA, Glomerulonephritis, MPO-ANCA
A case study reported favorable outcomes using oral prednisolone and losartan in a patient with ANCA-related glomerulonephritis. This combination therapy was effective in managing the disease, suggesting that treatment regimens could be tailored based on disease activity observed in renal histology .
Management of Lupus Nephritis and Hypertension
Keywords: Lupus Nephritis, Hypertension, Proteinuria
In patients with lupus nephritis and hypertension, losartan was found to be more effective than extended-release nifedipine in reducing proteinuria while maintaining similar blood pressure control. This indicates that losartan may offer additional renal protective benefits in this patient population .
Steroid-Sparing in Camurati-Engelmann Disease
Keywords: Camurati-Engelmann Disease, Steroid-Sparing, TGF-β1
Losartan has been used successfully as a steroid-sparing adjunct in a patient with refractory Camurati-Engelmann disease. By downregulating TGF-β1, losartan helped alleviate symptoms and reduce the need for high-dose steroids, highlighting its potential in managing this rare condition .
Conclusion
The combination of prednisone and losartan offers significant therapeutic benefits across various conditions, including kidney diseases, inflammatory disorders, and fibrosis. These findings underscore the potential of these drugs to work synergistically, providing enhanced efficacy and protection in clinical settings.
Sources and full results
Most relevant research papers on this topic
AngII-induced glomerular mesangial cell proliferation inhibited by losartan via changes in intracellular calcium ion concentration
Losartan inhibits angiotensin II-induced glomerular mesangial cell proliferation by reducing TRPC6 expression and increasing intracellular calcium ion concentration.
Topical Losartan and Corticosteroid Additively Inhibit Corneal Stromal Myofibroblast Generation and Scarring Fibrosis After Alkali Burn Injury
Topical losartan and prednisolone acetate effectively reduce corneal scarring fibrosis after alkali burn injury in rabbits.
Prednisolone Co-Administered with Losartan Confers Renoprotection in Patients with IgA Nephropathy
Prednisolone combined with losartan is more effective than prednisolone alone in reducing proteinuria and protecting renal function in patients with IgA nephropathy.
Protective effects of losartan on renal tubular of patients with nephrotic syndrome
Losartan has a protective effect on renal function in patients with nephrotic syndrome, reducing urinary protein levels and other indicators.
Effects of Prednisone,Enalapril and Losartan on Podocyte Molecules in Glomerulus of Adriamycin-Induced Nephrotic Rats
Prednisone, enalapril, and losartan may reduce proteinuria by stabilizing the expression and distribution of important podocyte molecules, nephrin and CD2AP.
Effect of Losartan in Complete Freund’s Adjuvant –Induced Arthritis in Rats
Losartan effectively reduces inflammation and improves blood circulation in rats with adjuvant-induced arthritis, potentially due to its anti-arthritic, hypolipidemic, antioxidant, and anti-anemic properties.
A favourable outcome using oral prednisolone and losartan only in a patient with ANCA-related glomerulonephritis: a discrepancy between histological activity and MPO-ANCA.
Oral prednisolone and losartan can be effective in treating ANCA-related glomerulonephritis, with therapy adjusting based on renal histology activity.
DOI